BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 11242107)

  • 1. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
    Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
    Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
    Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
    Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
    Nanri T; Uike N; Kawakita T; Iwanaga E; Mitsuya H; Asou N
    Genes Chromosomes Cancer; 2010 Mar; 49(3):237-41. PubMed ID: 19953636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
    Pabst T; Mueller BU
    Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
    Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
    Tokita K; Maki K; Mitani K
    Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.
    Cleaves R; Wang QF; Friedman AD
    Oncogene; 2004 Jan; 23(3):716-25. PubMed ID: 14737106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia.
    Benthaus T; Schneider F; Mellert G; Zellmeier E; Schneider S; Kakadia PM; Hiddemann W; Bohlander SK; Feuring-Buske M; Braess J; Spiekermann K; Dufour A
    Br J Haematol; 2008 Oct; 143(2):230-9. PubMed ID: 18752591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
    Rangatia J; Vangala RK; Singh SM; Peer Zada AA; Elsässer A; Kohlmann A; Haferlach T; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Jul; 22(30):4760-4. PubMed ID: 12879022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of CCAAT/enhancer binding protein alpha gene mutations in acute myeloid leukemia].
    Zhao JM; Wang HW; Xu ZF; Zhu L; Bai B; Ge XY
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):299-302. PubMed ID: 15949295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
    Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
    Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
    J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.
    Pabst T; Stillner E; Neuberg D; Nimer S; Willman CL; List AF; Melo JV; Tenen DG; Mueller BU
    Br J Haematol; 2006 May; 133(4):400-2. PubMed ID: 16643447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C/EBPalpha in leukemogenesis: identity and origin of the leukemia-initiating cell.
    Schuster MB; Porse BT
    Biofactors; 2009; 35(3):227-31. PubMed ID: 19322763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage.
    Porse BT; Bryder D; Theilgaard-Mönch K; Hasemann MS; Anderson K; Damgaard I; Jacobsen SE; Nerlov C
    J Exp Med; 2005 Jul; 202(1):85-96. PubMed ID: 15983063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma.
    Tan EH; Hooi SC; Laban M; Wong E; Ponniah S; Wee A; Wang ND
    Cancer Res; 2005 Nov; 65(22):10330-7. PubMed ID: 16288022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.